Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Sirtuin 7: a new marker of aggressiveness in prostate cancer.

Haider R, Massa F, Kaminski L, Clavel S, Djabari Z, Robert G, Laurent K, Michiels JF, Durand M, Ricci JE, Tanti JF, Bost F, Ambrosetti D.

Oncotarget. 2017 Aug 24;8(44):77309-77316. doi: 10.18632/oncotarget.20468. eCollection 2017 Sep 29.

2.

Implication of REDD1 in the activation of inflammatory pathways.

Pastor F, Dumas K, Barthélémy MA, Regazzetti C, Druelle N, Peraldi P, Cormont M, Tanti JF, Giorgetti-Peraldi S.

Sci Rep. 2017 Aug 1;7(1):7023. doi: 10.1038/s41598-017-07182-z.

3.

ERK1 is dispensable for mouse pancreatic beta cell function but is necessary for glucose-induced full activation of MSK1 and CREB.

Leduc M, Richard J, Costes S, Muller D, Varrault A, Compan V, Mathieu J, Tanti JF, Pagès G, Pouyssegur J, Bertrand G, Dalle S, Ravier MA.

Diabetologia. 2017 Oct;60(10):1999-2010. doi: 10.1007/s00125-017-4356-6. Epub 2017 Jul 18.

PMID:
28721437
4.

The energy disruptor metformin targets mitochondrial integrity via modification of calcium flux in cancer cells.

Loubiere C, Clavel S, Gilleron J, Harisseh R, Fauconnier J, Ben-Sahra I, Kaminski L, Laurent K, Herkenne S, Lacas-Gervais S, Ambrosetti D, Alcor D, Rocchi S, Cormont M, Michiels JF, Mari B, Mazure NM, Scorrano L, Lacampagne A, Gharib A, Tanti JF, Bost F.

Sci Rep. 2017 Jul 11;7(1):5040. doi: 10.1038/s41598-017-05052-2.

5.

Transfer of dysbiotic gut microbiota has beneficial effects on host liver metabolism.

Nicolas S, Blasco-Baque V, Fournel A, Gilleron J, Klopp P, Waget A, Ceppo F, Marlin A, Padmanabhan R, Iacovoni JS, Tercé F, Cani PD, Tanti JF, Burcelin R, Knauf C, Cormont M, Serino M.

Mol Syst Biol. 2017 Mar 16;13(3):921. doi: 10.15252/msb.20167356.

6.

DNA Damage and the Activation of the p53 Pathway Mediate Alterations in Metabolic and Secretory Functions of Adipocytes.

Vergoni B, Cornejo PJ, Gilleron J, Djedaini M, Ceppo F, Jacquel A, Bouget G, Ginet C, Gonzalez T, Maillet J, Dhennin V, Verbanck M, Auberger P, Froguel P, Tanti JF, Cormont M.

Diabetes. 2016 Oct;65(10):3062-74. doi: 10.2337/db16-0014. Epub 2016 Jul 7.

7.

Inhibition of the MAP3 kinase Tpl2 protects rodent and human β-cells from apoptosis and dysfunction induced by cytokines and enhances anti-inflammatory actions of exendin-4.

Varin EM, Wojtusciszyn A, Broca C, Muller D, Ravier MA, Ceppo F, Renard E, Tanti JF, Dalle S.

Cell Death Dis. 2016 Jan 21;7:e2065. doi: 10.1038/cddis.2015.399.

8.

Energy disruptors: rising stars in anticancer therapy?

Bost F, Decoux-Poullot AG, Tanti JF, Clavel S.

Oncogenesis. 2016 Jan 18;5:e188. doi: 10.1038/oncsis.2015.46. Review.

9.

Maintenance of Macrophage Redox Status by ChREBP Limits Inflammation and Apoptosis and Protects against Advanced Atherosclerotic Lesion Formation.

Sarrazy V, Sore S, Viaud M, Rignol G, Westerterp M, Ceppo F, Tanti JF, Guinamard R, Gautier EL, Yvan-Charvet L.

Cell Rep. 2015 Oct 6;13(1):132-144. doi: 10.1016/j.celrep.2015.08.068. Epub 2015 Sep 24.

10.

The Tpl2 Kinase Regulates the COX-2/Prostaglandin E2 Axis in Adipocytes in Inflammatory Conditions.

Berthou F, Ceppo F, Dumas K, Massa F, Vergoni B, Alemany S, Cormont M, Tanti JF.

Mol Endocrinol. 2015 Jul;29(7):1025-36. Epub 2015 May 28.

11.

Metformin-induced energy deficiency leads to the inhibition of lipogenesis in prostate cancer cells.

Loubière C, Goiran T, Laurent K, Djabari Z, Tanti JF, Bost F.

Oncotarget. 2015 Jun 20;6(17):15652-61.

12.

Inhibition of the GTPase Rac1 mediates the antimigratory effects of metformin in prostate cancer cells.

Dirat B, Ader I, Golzio M, Massa F, Mettouchi A, Laurent K, Larbret F, Malavaud B, Cormont M, Lemichez E, Cuvillier O, Tanti JF, Bost F.

Mol Cancer Ther. 2015 Feb;14(2):586-96. doi: 10.1158/1535-7163.MCT-14-0102. Epub 2014 Dec 19.

13.

Hypoxia inhibits Cavin-1 and Cavin-2 expression and down-regulates caveolae in adipocytes.

Regazzetti C, Dumas K, Lacas-Gervais S, Pastor F, Peraldi P, Bonnafous S, Dugail I, Le Lay S, Valet P, Le Marchand-Brustel Y, Tran A, Gual P, Tanti JF, Cormont M, Giorgetti-Peraldi S.

Endocrinology. 2015 Mar;156(3):789-801. doi: 10.1210/en.2014-1656. Epub 2014 Dec 18.

PMID:
25521582
14.

[Implication of MAP kinases in obesity-induced inflammation and insulin resistance].

Ceppo F, Jager J, Berthou F, Giorgetti-Peraldi S, Cormont M, Bost F, Tanti JF.

Biol Aujourdhui. 2014;208(2):97-107. doi: 10.1051/jbio/2014014. Epub 2014 Sep 8. Review. French.

PMID:
25190570
15.

Implication of the Tpl2 kinase in inflammatory changes and insulin resistance induced by the interaction between adipocytes and macrophages.

Ceppo F, Berthou F, Jager J, Dumas K, Cormont M, Tanti JF.

Endocrinology. 2014 Mar;155(3):951-64. doi: 10.1210/en.2013-1815. Epub 2014 Jan 1.

PMID:
24424060
16.

Rab4b controls an early endosome sorting event by interacting with the γ-subunit of the clathrin adaptor complex 1.

Perrin L, Lacas-Gervais S, Gilleron J, Ceppo F, Prodon F, Benmerah A, Tanti JF, Cormont M.

J Cell Sci. 2013 Nov 1;126(Pt 21):4950-62. doi: 10.1242/jcs.130575. Epub 2013 Sep 4. Erratum in: J Cell Sci. 2014 Jan 1;127(Pt 1):258. Laura, Perrin [corrected to Perrin, Laura]; Sandra, Lacas-Gervais [corrected to Lacas-Gervais, Sandra]; Jérôme, Gilleron [corrected to Gilleron, Jérôme]; Franck, Ceppo [corrected to Ceppo, Franck]; François, Prodon [corrected to Prodon, François]; Al.

17.

Caloric restriction modulates Mcl-1 expression and sensitizes lymphomas to BH3 mimetic in mice.

Meynet O, Zunino B, Happo L, Pradelli LA, Chiche J, Jacquin MA, Mondragón L, Tanti JF, Taillan B, Garnier G, Reverso-Meinietti J, Mounier N, Michiels JF, Michalak EM, Carles M, Scott CL, Ricci JE.

Blood. 2013 Oct 3;122(14):2402-11. doi: 10.1182/blood-2013-01-478651. Epub 2013 Aug 21.

18.

[New perspectives for metformin in cancer therapy].

Loubière C, Dirat B, Tanti JF, Bost F.

Ann Endocrinol (Paris). 2013 May;74(2):130-6. doi: 10.1016/j.ando.2013.02.002. Epub 2013 Apr 12. Review. French.

PMID:
23587351
19.

Implication of inflammatory signaling pathways in obesity-induced insulin resistance.

Tanti JF, Ceppo F, Jager J, Berthou F.

Front Endocrinol (Lausanne). 2013 Jan 8;3:181. doi: 10.3389/fendo.2012.00181. eCollection 2012.

20.

Regulated in development and DNA damage responses -1 (REDD1) protein contributes to insulin signaling pathway in adipocytes.

Regazzetti C, Dumas K, Le Marchand-Brustel Y, Peraldi P, Tanti JF, Giorgetti-Peraldi S.

PLoS One. 2012;7(12):e52154. doi: 10.1371/journal.pone.0052154. Epub 2012 Dec 18.

21.

Sestrin2 integrates Akt and mTOR signaling to protect cells against energetic stress-induced death.

Ben-Sahra I, Dirat B, Laurent K, Puissant A, Auberger P, Budanov A, Tanti JF, Bost F.

Cell Death Differ. 2013 Apr;20(4):611-9. doi: 10.1038/cdd.2012.157. Epub 2012 Dec 14.

22.

Adipose tissue microRNAs as regulators of CCL2 production in human obesity.

Arner E, Mejhert N, Kulyté A, Balwierz PJ, Pachkov M, Cormont M, Lorente-Cebrián S, Ehrlund A, Laurencikiene J, Hedén P, Dahlman-Wright K, Tanti JF, Hayashizaki Y, Rydén M, Dahlman I, van Nimwegen E, Daub CO, Arner P.

Diabetes. 2012 Aug;61(8):1986-93. doi: 10.2337/db11-1508. Epub 2012 Jun 11.

23.

Prevention of mutagenesis: new potential mechanisms of metformin action in neoplastic cells.

Bost F, Ben-Sahra I, Tanti JF.

Cancer Prev Res (Phila). 2012 Apr;5(4):503-6. doi: 10.1158/1940-6207.CAPR-12-0085.

24.

Metformin and cancer therapy.

Bost F, Sahra IB, Le Marchand-Brustel Y, Tanti JF.

Curr Opin Oncol. 2012 Jan;24(1):103-8. doi: 10.1097/CCO.0b013e32834d8155. Review.

PMID:
22123231
25.

Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1.

Ben Sahra I, Regazzetti C, Robert G, Laurent K, Le Marchand-Brustel Y, Auberger P, Tanti JF, Giorgetti-Peraldi S, Bost F.

Cancer Res. 2011 Jul 1;71(13):4366-72. doi: 10.1158/0008-5472.CAN-10-1769. Epub 2011 May 3.

26.

Deficiency in the extracellular signal-regulated kinase 1 (ERK1) protects leptin-deficient mice from insulin resistance without affecting obesity.

Jager J, Corcelle V, Grémeaux T, Laurent K, Waget A, Pagès G, Binétruy B, Le Marchand-Brustel Y, Burcelin R, Bost F, Tanti JF.

Diabetologia. 2011 Jan;54(1):180-9. doi: 10.1007/s00125-010-1944-0. Epub 2010 Oct 15.

PMID:
20953578
27.

The combination of metformin and 2 deoxyglucose inhibits autophagy and induces AMPK-dependent apoptosis in prostate cancer cells.

Ben Sahra I, Tanti JF, Bost F.

Autophagy. 2010 Jul 1;6(5):670-671. doi: 10.4161/auto.6.5.12434.

PMID:
28157435
28.
29.

Metformin in cancer therapy: a new perspective for an old antidiabetic drug?

Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F.

Mol Cancer Ther. 2010 May;9(5):1092-9. doi: 10.1158/1535-7163.MCT-09-1186. Epub 2010 May 4. Review.

30.

Apelin and APJ regulation in adipose tissue and skeletal muscle of type 2 diabetic mice and humans.

Dray C, Debard C, Jager J, Disse E, Daviaud D, Martin P, Attané C, Wanecq E, Guigné C, Bost F, Tanti JF, Laville M, Vidal H, Valet P, Castan-Laurell I.

Am J Physiol Endocrinol Metab. 2010 Jun;298(6):E1161-9. doi: 10.1152/ajpendo.00598.2009. Epub 2010 Mar 16.

31.

Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells.

Ben Sahra I, Laurent K, Giuliano S, Larbret F, Ponzio G, Gounon P, Le Marchand-Brustel Y, Giorgetti-Peraldi S, Cormont M, Bertolotto C, Deckert M, Auberger P, Tanti JF, Bost F.

Cancer Res. 2010 Mar 15;70(6):2465-75. doi: 10.1158/0008-5472.CAN-09-2782. Epub 2010 Mar 9.

32.

Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy.

Risson V, Mazelin L, Roceri M, Sanchez H, Moncollin V, Corneloup C, Richard-Bulteau H, Vignaud A, Baas D, Defour A, Freyssenet D, Tanti JF, Le-Marchand-Brustel Y, Ferrier B, Conjard-Duplany A, Romanino K, Bauché S, Hantaï D, Mueller M, Kozma SC, Thomas G, Rüegg MA, Ferry A, Pende M, Bigard X, Koulmann N, Schaeffer L, Gangloff YG.

J Cell Biol. 2009 Dec 14;187(6):859-74. doi: 10.1083/jcb.200903131.

33.

Insulin induces REDD1 expression through hypoxia-inducible factor 1 activation in adipocytes.

Regazzetti C, Bost F, Le Marchand-Brustel Y, Tanti JF, Giorgetti-Peraldi S.

J Biol Chem. 2010 Feb 19;285(8):5157-64. doi: 10.1074/jbc.M109.047688. Epub 2009 Dec 8.

34.

Tpl2 kinase is upregulated in adipose tissue in obesity and may mediate interleukin-1beta and tumor necrosis factor-{alpha} effects on extracellular signal-regulated kinase activation and lipolysis.

Jager J, Grémeaux T, Gonzalez T, Bonnafous S, Debard C, Laville M, Vidal H, Tran A, Gual P, Le Marchand-Brustel Y, Cormont M, Tanti JF.

Diabetes. 2010 Jan;59(1):61-70. doi: 10.2337/db09-0470. Epub 2009 Oct 6.

35.

Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation.

Tanti JF, Jager J.

Curr Opin Pharmacol. 2009 Dec;9(6):753-62. doi: 10.1016/j.coph.2009.07.004. Epub 2009 Aug 13. Review.

PMID:
19683471
36.

Involvement of TNF-alpha in abnormal adipocyte and muscle sortilin expression in obese mice and humans.

Kaddai V, Jager J, Gonzalez T, Najem-Lendom R, Bonnafous S, Tran A, Le Marchand-Brustel Y, Gual P, Tanti JF, Cormont M.

Diabetologia. 2009 May;52(5):932-40. doi: 10.1007/s00125-009-1273-3. Epub 2009 Feb 14.

PMID:
19219422
37.

The inflammatory receptor CD40 is expressed on human adipocytes: contribution to crosstalk between lymphocytes and adipocytes.

Poggi M, Jager J, Paulmyer-Lacroix O, Peiretti F, Gremeaux T, Verdier M, Grino M, Stepanian A, Msika S, Burcelin R, de Prost D, Tanti JF, Alessi MC.

Diabetologia. 2009 Jun;52(6):1152-63. doi: 10.1007/s00125-009-1267-1. Epub 2009 Jan 31.

PMID:
19183933
38.

Hypoxia decreases insulin signaling pathways in adipocytes.

Regazzetti C, Peraldi P, Grémeaux T, Najem-Lendom R, Ben-Sahra I, Cormont M, Bost F, Le Marchand-Brustel Y, Tanti JF, Giorgetti-Peraldi S.

Diabetes. 2009 Jan;58(1):95-103. doi: 10.2337/db08-0457. Epub 2008 Nov 4.

39.

The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.

Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le Marchand-Brustel Y, Bost F.

Oncogene. 2008 Jun 5;27(25):3576-86. doi: 10.1038/sj.onc.1211024. Epub 2008 Jan 21.

PMID:
18212742
40.

p38MAP Kinase activity is required for human primary adipocyte differentiation.

Aouadi M, Jager J, Laurent K, Gonzalez T, Cormont M, Binétruy B, Le Marchand-Brustel Y, Tanti JF, Bost F.

FEBS Lett. 2007 Dec 11;581(29):5591-6. Epub 2007 Nov 13.

41.

Osmotic regulation of cellular glucose uptake.

Gual P, Gonzalez T, Gremeaux T, Le Marchand-Brustel Y, Tanti JF.

Methods Enzymol. 2007;428:343-54.

PMID:
17875428
42.

Metabolic endotoxemia initiates obesity and insulin resistance.

Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C, Waget A, Delmée E, Cousin B, Sulpice T, Chamontin B, Ferrières J, Tanti JF, Gibson GR, Casteilla L, Delzenne NM, Alessi MC, Burcelin R.

Diabetes. 2007 Jul;56(7):1761-72. Epub 2007 Apr 24.

43.

C3H/HeJ mice carrying a toll-like receptor 4 mutation are protected against the development of insulin resistance in white adipose tissue in response to a high-fat diet.

Poggi M, Bastelica D, Gual P, Iglesias MA, Gremeaux T, Knauf C, Peiretti F, Verdier M, Juhan-Vague I, Tanti JF, Burcelin R, Alessi MC.

Diabetologia. 2007 Jun;50(6):1267-76. Epub 2007 Apr 11.

PMID:
17426960
44.

Hepatocyte growth factor induces glucose uptake in 3T3-L1 adipocytes through A Gab1/phosphatidylinositol 3-kinase/Glut4 pathway.

Bertola A, Bonnafous S, Cormont M, Anty R, Tanti JF, Tran A, Le Marchand-Brustel Y, Gual P.

J Biol Chem. 2007 Apr 6;282(14):10325-32. Epub 2007 Feb 6.

45.

[Obesity, diabetes and insulin resistance. Alterations of insulin signalling].

Le Marchand-Brustel Y, Gual P, Aouadi M, Grémeaux T, Binétruy B, Bost F, Tanti JF.

J Soc Biol. 2006;200(1):93-7. Review. French.

PMID:
17144167
46.

Interleukin-1beta-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression.

Jager J, Grémeaux T, Cormont M, Le Marchand-Brustel Y, Tanti JF.

Endocrinology. 2007 Jan;148(1):241-51. Epub 2006 Oct 12.

47.

Differential effects of IRS1 phosphorylated on Ser307 or Ser632 in the induction of insulin resistance by oxidative stress.

Bloch-Damti A, Potashnik R, Gual P, Le Marchand-Brustel Y, Tanti JF, Rudich A, Bashan N.

Diabetologia. 2006 Oct;49(10):2463-73. Epub 2006 Aug 3.

PMID:
16896943
48.

Enigma interacts with adaptor protein with PH and SH2 domains to control insulin-induced actin cytoskeleton remodeling and glucose transporter 4 translocation.

Barrès R, Grémeaux T, Gual P, Gonzalez T, Gugenheim J, Tran A, Le Marchand-Brustel Y, Tanti JF.

Mol Endocrinol. 2006 Nov;20(11):2864-75. Epub 2006 Jun 27.

49.

Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage.

Knauf C, Cani PD, Perrin C, Iglesias MA, Maury JF, Bernard E, Benhamed F, Grémeaux T, Drucker DJ, Kahn CR, Girard J, Tanti JF, Delzenne NM, Postic C, Burcelin R.

J Clin Invest. 2005 Dec;115(12):3554-63.

50.

The interaction between the adaptor protein APS and Enigma is involved in actin organisation.

Barrès R, Gonzalez T, Le Marchand-Brustel Y, Tanti JF.

Exp Cell Res. 2005 Aug 15;308(2):334-44.

PMID:
15946664

Supplemental Content

Support Center